Evidence map›Paper›PMID 36995373›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2023

At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study.

Julia Wigren Byström, Linnea Vikström, Ebba Rosendal, Remigius Gröning, Yong-Dae Gwon, Emma Nilsson, Atin Sharma, Akbar Espaillat, Leo Hanke, Gerald McInerney and 12 more

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04368013 (Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04368013 unknown statusnot on this map

Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial

TypeobservationalSponsorJohan NormarkRan2020 to 2026Enrolled550ConditionsCOVID-19ArmsExtended sampling and procedures
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Julia Wigren ByströmXerum AB, Umeå, Sweden.
Linnea VikströmDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Ebba RosendalLaboratory for Molecular Infection Medicine Sweden, Umeå University, Umeå, Sweden.
Remigius GröningDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Yong-Dae GwonDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Emma NilssonLaboratory for Molecular Infection Medicine Sweden, Umeå University, Umeå, Sweden.
Atin SharmaDepartment of Molecular Biology, Umeå University, Umeå, Sweden.
Akbar EspaillatDepartment of Molecular Biology, Umeå University, Umeå, Sweden.
Leo HankeDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Gerald McInerneyDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Andrea PuharDepartment of Molecular Biology, Umeå University, Umeå, Sweden.
Felipe CavaDepartment of Molecular Biology, Umeå University, Umeå, Sweden.
Gunilla B Karlsson HedestamDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Therese ThunbergDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Tor MonsenDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Fredrik ElghDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Magnus EvanderDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Anders F JohanssonDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Anna K ÖverbyLaboratory for Molecular Infection Medicine Sweden, Umeå University, Umeå, Sweden.
Clas AhlmDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Johan NormarkDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Mattias Ne ForsellDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Umeå University · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundThe current SARS-CoV-2 pandemic has highlighted a need for easy and safe blood sampling in combination with accurate serological methodology. Venipuncture for testing is usually performed by trained staff at healthcare centres. Long travel distances to healthcare centres in rural regions may introduce a bias of testing towards relatively large communities with closer access. Rural regions are therefore often not represented in population-based data.AimThe aim of this retrospective cohort study was to develop and implement a strategy for at-home testing in a rural region of Sweden during spring 2021, and to evaluate its role to provide equal health care for its inhabitants.MethodsWe developed a sensitive method to measure antibodies to the S-protein of SARS-CoV-2 and optimised this assay for clinical use together with a strategy of at-home capillary blood sampling.ResultsWe demonstrated that our ELISA gave comparable results after analysis of capillary blood or serum from SARS-CoV-2-experienced individuals. We demonstrated stability of the assay under conditions that reflected temperature and humidity during winter or summer. By assessment of capillary blood samples from 4,122 individuals, we could show both feasibility of the strategy and that implementation shifted the geographical spread of testing in favour of rural areas.ConclusionImplementation of at-home sampling enabled citizens living in remote rural areas access to centralised and sensitive laboratory antibody tests. The strategy for testing used here could therefore enable disease control authorities to get rapid access to information concerning immunity to infectious diseases, even across vast geographical distance.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralCOVID-19 TestingHumansRetrospective StudiesSwedenAntibodies, Viralcoronavirus disease (COVID-19)laboratorysurveillanceSweden

Identifiers

PMID36995373
PMCPMC10064644
OpenAlexW4361304021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.